There are approximately 50 million chronic carriers of hepatitis B virus (HBV) (Gut 1996; 38 (suppl 2): S5-S12)
By any yardstick, hepatitis B stands out as an important public health problem warranting high priority efforts, prevention, and control. Approximately 300 million people -over 5% of the world's population -are chronic carriers of the hepatitis B virus (HBV), of whom it is estimated that 25-30% will die of the sequelae of their infection, principally cirrhosis and hepatocellular carcinoma. [1] [2] [3] In regions of the world where hepatitis B is highly endemic, HBV accounts for around 3% of the total mortality, ranking with other vaccine preventable childhood diseases such as measles, tetanus, pertussis, and polio. Epidemiology of HBV in sub-Saharan Africa The size and diversity of the African continent, the dispersion of much of its population among vast rural areas, and the frequent lack of resources mean that accurate determination of HBV carrier rates can be extremely difficult. Moreover, assessment of ongoing infectivity and potential precore mutant infection is limited by the lack of polymerase chain reaction testing for HBV-DNA in the great majority of centres. Nevertheless, the epidemiology of HBV infection has been extensively investigated in certain parts of sub-Saharan Africa.5-24 Table I shows the prevalence of hepatitis B surface antigen (HBsAg) and other HBV markers in some of the countries in subSaharan Africa. It is quite clear that the whole of sub-Saharan Africa falls into the high endemicity category (HBsAg carrier rates 9-20%). Between 56% and 98% of the adult population shows evidence of past exposure to and infection with HBV.
The epidemiology of HBV has been studied by various workers in West Africa. In this region, nearly everyone is infected during childhood.6 7 In contrast with the situation in parts of the Far East where a high proportion of the population acquires infection perinatally, HBV infection of newborns is uncommon in west Africa. However, infection rates increase rapidly from the age of 6 months so that, by the age of 2 years, 40% of west African children have already been infected with HBV and 15% have developed persistent infection. By the age of 10 years, 90% of children have become infected and 20% have become chronic carriers. The precise mode of transmission of the virus in west Africa is unknown but a number of studies have attempted to look at some of the factors that may be responsible for the apparently high rate of transmission, particularly among young children. A study from Liberia8 looked at the prevalence of hepatitis B among children aged up to 4 years. Children born to mothers who were carriers of HBsAg had significantly higher age specific incidence and prevalence of HBV infection. However, it was estimated that only a minor proportion (less than 5%) of hepatitis B infection in Liberia was due to perinatal transmission from mothers.
Another study from Liberia9 attempted to link the high prevalence of HBV infection to parasitic infection (onchocerciasis). In a rubber plantation where onchocerciasis was also common, the HBsAg carrier rate was 30% compared with a carrier rate of 13% elsewhere in Liberia where onchocerciasis was rare. Another study looked at hepatitis B immunisation in pregnancy. 33 HevacB was given to pregnant Senegalese women to improve passive protection of their children. The vaccine was without side effects in mothers and their newborns. After three injections of hepatitis B vaccine, 77.4% of the mothers were found to have anti-HBs compared with 44.5% of nonimmunised mothers. The vaccination did not significantly reduce the number of HBsAg carrier mothers but it ensured the transmission of passive anti-HBs antibodies to 60% of the newborn babies as against 32% in children born to non-immunised mothers. However, such protection was of short duration and difficult to apply in rural areas of tropical Africa. Moreover, no protection was provided to those children born to HBeAg positive mothers, who represent a potential risk factor for infection of their babies.
Several studies have evaluated the simultaneous administration of hepatitis B vaccine and other vaccines. In one such study, the interaction of hepatitis B and DTP vaccine was investigated in Senegal.34 The immune response was evaluated when the vaccines were given either together or separately to children. The immune response to HBsAg vaccine and DTP vaccine injected simultaneously was equal to the immune response seen after each of these vaccines was given alone. Moreover, no adverse reactions were noted.
Simultaneous administration of hepatitis B and yellow fever vaccines was also studied in Senegalese children. 93 .8% if all HBV events were considered (HBsAg and anti-HBc positive) and 100% if only HBsAg events were considered. The protective effect was reflected in the levels of antiHBs antibodies in the vaccinated infants from blood samples taken three years after the booster; 97.5% had anti-HBs antibodies and the median anti-HBs titre was 200 mIU/ml.
Yvonnet et al reported the longterm persistence of anti-HBs antibody in 156 Senegalese children vaccinated using the schedule of zero, one, and two months with a booster at 12 months.40 Six years after the booster dose, 90.40/0 of the children had detectable anti-HBs antibodies, with 78. 1% having titres higher than 10 mIU/ml. The GMT was 60 mIU/ml. Females showed higher anti-HBs values than males. In a group of children who received no booster dose, anti-HBs antibodies were detectable seven years after the first dose. However, the GMT was lower (26 mIU/ml). Revaccination with a booster dose (56 children) led to an increase in the GMT to 469 mIU/ml two months later. The results show that a booster dose at five to six year intervals may be necessary to provide adequate anti-HBs levels.
Another study by the same group followed up the incidence of hepatitis B in 135 children vaccinated against hepatitis B and 143 children constituting the control group (vaccinated with DTP vaccine).41 Over the following six years, the incidence of hepatitis B was 1.5% per year in the group vaccinated against hepatitis B, compared with 11.5% per year in the control group. In the first four years, the protective efficacy of the vaccine was 100% but during the fifth and sixth years it fell to 67%. For maximum protection, another booster dose was recommended five years after the first booster.
Perhaps the best known study is the Gambia Hepatitis Intervention Study (GHIS Age  number  I  II  III  IV   Birth   1   BCG,HBV1  HBV1  6 weeks  2  OPV 1, DTP, HBV 2  HBV 2  HBV 1  HBV 1  10 weeks  3  OPV 2,DTP2  HBV2  HBV2  14 weeks  4  OPV 3, DTP 3  HBV 3  24-48 weeks  5  Measles, HBV 3  HBV 3  HBV 3 OPV: oral polio vaccine; DTP: diphtheria, tetanus, and pertussis.
for the prevention of hepatitis B infection in sub-Saharan Africa. The use of the hepatitis B immune globulin (HBIg) as an adjunct to vaccination has been advocated in some areas such as the Far East where perinatal transmission is common. The efficacy of hepatitis B vaccine alone is between 75 and 90%, while the efficacy when HBIg is added to hepatitis B vaccination is as high as 95%/o. The use of HBIg adds considerable cost to the treatment, however, and is practicable only in countries that can establish and pay for routine resting of pregnant women. It is more cost effective to devote available resources to routine infant immunisation with vaccine alone, and most developing countries will elect to forego use of HBIg.
The schedule of administration of hepatitis B vaccine should be coordinated with the delivery of the other EPI vaccines. Ideally, the first dose of hepatitis B vaccine should be given as soon as possible after birth and, in all cases, at the first immunisation contact. The second dose should be given at the next immunisation contact, and the third dose with the third, fourth or fifth contact. The reason for this variation in scheduling of the third dose of hepatitis B vaccine is that, the longer the interval between the second and third doses, the higher the maximal protective antibody titre achieved. While the achievement of such maximal titres may be theoretically desirable, it is not clear whether such levels have any impact on the duration of protective immunity. The decision to delay the third dose until the time of measles immunisation must be weighed against the possibility that a third dose will not be delivered at all because of lower overall measles immunisation coverage rates. Africa where perinatal transmission is uncommon. Option IV permits simultaneous delivery with DPT and anticipates the future availability of a combined DPT-hepatitis B vaccine.
As previously mentioned, a number of hepatitis B vaccination programmes have been initiated in sub-Saharan Africa. Perhaps the best known programme is the GHIS, which is the first programme to achieve national coverage in this region. Other important programmes in Kenya and Cameroon, supported by the International Task Force on Hepatitis B Immunisation, have produced a catalytic effect on the launching of hepatitis B immunisation programmes throughout Africa.
A great deal has been learned from the existing hepatitis B vaccination programmes. For the vaccine to be successfully incorporated into the EPI, comprehensive training programmes for health staff are absolutely essential. Health staff need updated information that a safe, effective vaccine now exists at an affordable price for public sector programmes. They also need to know that hepatitis B vaccine can safely be delivered with the other EPI vaccines and that it has very minor side effects. The administrators and the general public also need to know about the disease, its consequences, and its prevention, including hepatitis B vaccination. They need to know that the vaccine is safe, and that three doses are required for full protection. They also need to be kept informed as to the schedule of hepatitis B vaccination.
Vaccines Kiire: Another point is that, in an endemic situation, the recommendation may be slightly different from that where contact with a hepatitis B carrier is unlikely. In the Gambian study, even children with very low antibody titres mounted a fairly good anamnestic response when they were exposed to infection, and anyway were unlikely to become chronic carriers.
Hollinger: In reviewing data on durability of immunity, it is important to recognise that results have been obtained from immunisation with the plasma derived vaccine. This seems to be a stronger immunogen than the recombinant vaccine, perhaps because it has some pre-S material in it and also because of its conformation.
Goudeau: To achieve the same immunisation pattern, you need 20 Kug of the recombinant vaccine and only 5 ,ug of the plasma derived one.
Hollinger: We probably need to wait a little longer to see whether the recombinant vaccines are less immunogenic or whether it has to do with the way in which they given. We just don't know what the longterm durability is likely to be with either the plasma derived or the recombinant vaccines, especially the latter. Zuckerman: Would you recommend a booster dose if someone's antibody titre declines to below 100 IU/1 and that person is at risk of exposure to HBV -a surgeon, for example?
Gust: Under those circumstances, boosting is usually recommended, because you know it will do no harm and it may possibly be of benefit. There is, however, no strong scientific basis for that position. Toukan: Rather than talking about durability of antibody response, perhaps we should be investigating the durability of the immune response in an individual?
Lansang: In the Philippines a few years ago, we tested a single dose of 1-5 ,ug vaccine against three doses. After three years, we retested these children and many of them no longer had detectable antibody. When 
